about
Arsenic in drinking water and prostate cancer in Illinois counties: an ecologic studyLong-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimatesIs prostate cancer incidence worldwide linked to artificial light at night exposures? Review of earlier findings and analysis of current trends.Calibrating disease progression models using population data: a critical precursor to policy development in cancer controlCirculating Folate and Vitamin B12 and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls.Segregation analyses of 1,476 population-based Australian families affected by prostate cancer.Genetics of prostate cancer: too many loci, too few genesSymptomatic diagnosis of prostate cancer in primary care: a structured review.Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies.Long noncoding RNAs as putative biomarkers for prostate cancer detection.Expected population impacts of discontinued prostate-specific antigen screening.Technology Insight: tuning into the genetic orchestra using microarrays--limitations of DNA microarrays in clinical practice.Urinary estrogen metabolites and prostate cancer risk: a pilot study.Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense mutation G84E.The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.Quantifying the role of PSA screening in the US prostate cancer mortality decline.What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models.Cytogenetics and molecular genetics of cancer of the prostate.Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha-tocolpherol, beta-carotene cancer prevention (ATBC) studyCurrent Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy.RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.Epidemiological and clinical investigations among employees in a former herbicide production process.The role of targeted focal therapy in the management of low-risk prostate cancer: update on current challenges.Prostate-specific antigen and detection of prostate cancer: What have we learned and what should we recommend for screening?Systematic, evidence-based discovery of biomarkers at the NCI.Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening.Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening.Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC)Beyond PSA: the next generation of prostate cancer biomarkers.The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex.Quantifying lead-time bias in risk factor studies of cancer through simulation.Common cancers in centenarians.Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies.The utility of quantitative ADC values for differentiating high-risk from low-risk prostate cancer: a systematic review and meta-analysis.Habitual Tea Consumption Reduces Prostate Cancer Risk in Vietnamese Men: a Case-Control StudyThe ONCOTYROL Prostate Cancer Outcome and Policy Model: Effect of Prevalence Assumptions on the Benefit-Harm Balance of Screening.Incidental fleurodeoxyglucose uptake in the prostateHigh levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study.Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition.Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
P2860
Q26343779-67406D54-35E8-452D-AE60-1B4AA04744F5Q28251617-096D8ACB-D772-47B8-B8B6-92D9E4943D52Q30251683-287829E7-5B09-45AF-887D-32E4B089D7C5Q30496883-1B31DD18-F323-4A7F-B36A-F40F389306C9Q31072425-59E1694B-8123-4A3B-B437-93F22A35C4A0Q34020691-E4031E84-605D-4FE4-9302-5D47499560FCQ34078064-A5DDF01F-A3D7-43CB-855D-D321E9178B27Q34247769-EFBA2EEB-BD22-46A4-A872-5284906ED1D9Q34299696-45A01664-E6DE-4606-B3FF-7A546FB1E098Q34409743-2706AA0F-7C87-454C-BB3B-DE5F3CDAF8F2Q34458237-13A067F2-922C-47AB-874C-F3F54E0F5E4DQ34563757-9A4A018E-3C9F-4F0E-8D86-712BFD078FF2Q34567583-11773E80-2FCA-4F4A-93CC-FD8F5CEEC7DFQ34606248-FE1C7B7D-D3BF-4B15-9E43-2F3DE32B44A1Q34699785-C61934ED-9C50-44AD-81E9-9F396351B318Q34720042-E33C153A-27D1-4B70-BA20-FB3C5B63345DQ34963971-006CD58C-0C99-4E85-8E22-6C477124968BQ34984193-66422972-DC4C-421B-9EC1-28D2390A3E53Q35957484-02BC52EF-EA1B-4F29-B897-5E99D2BF5DCDQ35977609-30F15D5D-E67A-4C04-821A-74A9C1573CACQ36025180-89E404C2-E42C-440D-90CB-11D263FD92F9Q36534818-91D47178-37D7-475C-A3AF-C1095B09D7B7Q36546399-0A0CF122-D14E-4519-8D77-D8DA59557899Q36563631-07E435DF-3DCB-4545-A2E4-575E7A13B0C6Q36922015-1377E2C4-370B-458E-A085-AB2ECDB8C7C2Q37070417-DB799D9B-31E1-4D0B-951F-0BCDAA6EE83FQ37160706-08A37BB0-558B-42AF-B96E-1FF9B6D423B0Q37175475-B5458B5D-D249-4DDE-8431-ECFED83DDD94Q37238101-D8B9EBB5-A78C-442E-8B58-23F530FBF861Q37266000-367F2DEE-207A-4838-89BF-F256D5594AECQ37339529-00D3BDF3-6E58-45D2-8589-97E9377A99C6Q37490455-BFA6057B-B8CA-4E86-BC49-35027E6FD22AQ38204779-E07E53F7-4890-4C47-A13F-096C7F44ED7FQ38937545-D2DFC88D-85D6-41E3-8A21-8158614A9432Q40403392-BBBCFD6E-0F0F-4395-BBA3-72B22C4C0C4FQ40936828-4CAB7E82-E096-4557-AAE6-9F4D3FC04023Q42419640-5CF684FD-A6CB-4213-B46F-F101106EEF65Q44675825-18D65384-817E-43A1-91B9-75FBEB51BEE7Q47094089-7D677E81-9D22-4709-B5FE-546E68592E04Q47787102-4E432481-CAE6-473D-A3F4-C4E7623D4F30
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Asymptomatic incidence and duration of prostate cancer.
@en
Asymptomatic incidence and duration of prostate cancer.
@nl
type
label
Asymptomatic incidence and duration of prostate cancer.
@en
Asymptomatic incidence and duration of prostate cancer.
@nl
prefLabel
Asymptomatic incidence and duration of prostate cancer.
@en
Asymptomatic incidence and duration of prostate cancer.
@nl
P2093
P1476
Asymptomatic incidence and duration of prostate cancer.
@en
P2093
P304
P356
10.1093/OXFORDJOURNALS.AJE.A009698
P407
P577
1998-10-01T00:00:00Z